Viracta Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2002
Net Income	-51.06	-49.2	-114.76	-19.02	-23.33	Upgrade
Depreciation & Amortization	0.49	0.21	0.18	0.03	0	Upgrade
Share-Based Compensation	7.65	13.55	5.54	0.35	1.75	Upgrade
Other Operating Activities	3.03	-0.02	90.19	2.58	-0.6	Upgrade
Operating Cash Flow	-39.89	-35.46	-18.85	-16.05	-22.19	Upgrade
Capital Expenditures	-0.14	-0.05	-0.25	-0.06	0	Upgrade
Acquisitions	0	0	17.14	0	0	Upgrade
Change in Investments	15.14	-53.82	0	0	-16.29	Upgrade
Other Investing Activities	-	-	-4	-	-	Upgrade
Investing Cash Flow	15	-53.87	12.89	-0.06	-16.29	Upgrade
Share Issuance / Repurchase	0.44	2.56	62.66	39.72	32.55	Upgrade
Debt Issued / Paid	0	19.99	-0.23	5.26	-2.05	Upgrade
Other Financing Activities	-	-	-	-	12.53	Upgrade
Financing Cash Flow	0.44	22.54	62.43	44.98	43.04	Upgrade
Net Cash Flow	-24.46	-66.78	56.47	28.87	4.57	Upgrade
Free Cash Flow	-40.03	-35.5	-19.1	-16.11	-22.19	Upgrade
Free Cash Flow Margin	-	-	-	-	-1070.19%	Upgrade
Free Cash Flow Per Share	-1.04	-0.94	-0.60	-49.61	-8.91	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).